brand logo

Am Fam Physician. 2024;110(3):313-314

Author disclosure: No relevant financial relationships.

Resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist, is conditionally approved for use in adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis (stages F2 to F3) to reduce liver fat accumulation and to prevent progression of and reverse fibrosis when combined with diet and exercise.1 Resmetirom was approved using the U.S. Food and Drug Administration accelerated approval pathway on the basis of histologic data and may be granted final, traditional approval if the ongoing confirmatory trial verifies clinical outcome benefit.2

DrugDosageDose formCost*
Resmetirom (Rezdiffra)80 mg once daily for patients weighing less than 100 kg (220 lb)
100 mg once daily for patients weighing more than 100 kg
60-mg, 80-mg, or 100-mg tablet$4,000
Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Continue Reading

More in AFP

Copyright © 2024 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.